Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Sep 30, 2026
Neuronetics, Inc. (STIM)
A forensic read on Neuronetics, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
F · Poor — capital at risk
Forensic grade
Distress
Financial health
-8.3
Distress distance
Clean
Earnings quality
3
Forensic signals
-7.7
P / E (ttm)
-174.3%
ROE
$251M
Market cap
0.00%
Dividend yield
99.2%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence, going concern, valuation). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Neuronetics, Inc. earns an F (Poor — capital at risk) forensic quality grade, and its balance-sheet distress test reads -8.3, placing it in the Distress zone. 3 forensic signals were flagged in its latest SEC filings, led by return on invested capital.
What the filings flag
-30.0%
FY2025
Return on invested capital.Return on invested capital is -30.0% in the latest fiscal year and rising across FY2023–FY2025 from -66.4%. After-tax operating profit was ($24M) in FY2023 and ($25M) in FY2025, with operating income at -42.8% of revenue in FY2023, -46.2% in FY2024 and -21.1% in FY2025. The capital base behind it grew +128% across FY2023–FY2025, from $36M to $83M, and the return did not fall doing it, so the dollars added over that window earned at least the -66.4% the older base was already earning.
+51.7%/yr
FY2023–FY2025
Share-count dilution.Diluted share count changed +130% over the last 2 years to FY2025 (+51.7%/yr). The count is growing — 28.7M shares in FY2023, 66.0M in FY2025: more stock was issued than repurchased over this window, so aggregate results grew faster than their per-share equivalents. That's ~51.7% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2023 has been diluted ~57%.
5% of rev
FY2025
Stock-based comp load.Stock-based compensation ran 5% of revenue in FY2025 — about $0.10 per diluted share. No cash left the business to pay it, which is why operating cash flow adds it back. Net of repurchases the diluted count still rose about 51.7% a year across FY2023–FY2025 and that rate is not falling, so total profit has to grow by that much annually before any of it reaches a share. Stock compensation is one source of that issuance; acquisition consideration, equity raises, convertibles and other employee plans also net into the count, and these figures do not separate them.
Key fundamentals
Latest Revenue$149.2M
Revenue Growth YoY+99.2%
Revenue CAGR (2yr)+44.6%
Net Margin-26.1%
Free Cash Flow-$21.2M
Return on Equity-174.3%
Debt / Equity6.54x
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Neuronetics, Inc.'s actual 10-K/10-Q/8-K filings?